Abstract
OBJECTIVES: Diagnostic utility of cytomegalovirus (CMV) DNA quantitative polymerase chain reaction
(qPCR) in inflammatory bowel disease (IBD) has not been established. We aimed to compare
diagnostic utility of qPCR for CMV in biopsy specimens with blood, serology, and histopathology.
MATERIALS AND METHODS: A total of 132 patients were included (92 ulcerative colitis [UC], 9 Crohn's disease,
and 31 unclassified IBD). Comparison between CMV IgM, CMV DNA qPCR in biopsy, in blood
and histopathology was done. Positive result in any of the test was considered as
CMV infection. Various risk factors for CMV association with IBD were analyzed.
RESULTS: Confirmed CMV infection was seen in 41 (31.1%) patients. Diagnostic sensitivity of
different assays was: DNA in biopsy seen in 37 (90.2%), DNA in blood in 19 (46.3%),
CMV IgM in 15 (36.5%), and histopathology in 8 (19.5%). Thirty-two UC cases were further
followed up for a median time of 14.0 (R: 3–31) months. They were grouped as group I – biopsy and blood DNA both positive
(14, 43.7%), Group II – biopsy positive and blood negative (17, 53.1%), and Group
III – biopsy negative but blood positive (1, 3.1%). CMV DNA viral load in Group I
was significantly higher (mean: 4.2 ± 1.0 log10 copies/mg) than Group II (mean: 3.2 ± 0.6 copies/mg) and Group III (viral load: 2.69
log10 copies/ml), P < 0.001. Steroid refractoriness was seen more in Group I cases (n = 9) P < 0.001. A cutoff of ≥2.5 log10 copies/mg of DNA in tissue was predictive for steroid refractoriness (AUROC = 0.84).
CONCLUSIONS: Quantitation of CMV DNA in intestinal biopsy is a useful diagnostic tool and can
predict response to steroid treatment in patients with UC.
Key words
Cytomegalovirus - inflammatory bowel disease - quantitative polymerase chain reaction
- ulcerative colitis